

# Clinical trials of vasopeptidase inhibitor for heart failure in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 vasopeptidase inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>omapatrilat vs enalapril</b>			
<b>OVERTURE , 2002</b> n=2886/2884 follow-up: 14.5 months	omapatrilat 40 mg once daily versus enalapril 10 mg twice daily	patients with NYHA II-IV heart failure	Parallel groups double blind 42 countries
<b>omapatrilat vs lisinopril</b>			
<b>IMPRESS , 2000</b> n=289/284 follow-up: 12 weeks (24 weeks)	omapatrilat target dose 40 mg daily versus lisinopril target dose 20mg daily	patients with NTHA II-IV congestive heart failure, LEVF <=40% , and receiving ACE inhibitor	Parallel groups double blind USA, canada

## References

### OVERTURE, 2002:

Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). *Circulation* 2002;106:920-6 [[12186794](#)]

Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA, , Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. *Am Heart J* 2005;150:257-62. [[16086927](#)] [10.1016/j.ahj.2004.09.056](#)

### IMPRESS, 2000:

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. *Lancet* 2000;356:615-20 [[10968433](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.